{"id":10070,"date":"2023-07-25T12:30:25","date_gmt":"2023-07-25T12:30:25","guid":{"rendered":"https:\/\/www.dhenne-avocat.sea-dev-and-sun.fr\/?p=10070"},"modified":"2026-10-23T16:22:54","modified_gmt":"2026-10-23T16:22:54","slug":"apixaban-case-in-france-priority-to-the-patentee","status":"publish","type":"post","link":"https:\/\/www.dhenne-avocats.fr\/ja\/apixaban-case-in-france-priority-to-the-patentee\/","title":{"rendered":"\u30d5\u30e9\u30f3\u30b9\u306b\u304a\u3051\u308bAPIXABAN\u4e8b\u4ef6\uff1a\u7279\u8a31\u6a29\u8005\u306e\u512a\u5148"},"content":{"rendered":"<p><br \/>\n<br \/>\n<\/p>\n<p>\u82f1\u56fd\u306e\u540c\u50da\u304c\u3001\u672c\u4ef6\u306b\u304a\u3051\u308b\u82f1\u56fd\u306e\u5224\u6c7a\u306b\u3064\u3044\u3066\u3001\u3059\u3067\u306b\u3082\u3063\u3068\u3082\u3089\u3057\u3055\uff08plausibility\uff09\u306e\u89b3\u70b9\u304b\u3089\u898b\u4e8b\u306a\u8a55\u91c8\u3092\u884c\u3063\u3066\u3044\u307e\u3059\uff08<a href=\"https:\/\/patentblog.kluweriplaw.com\/2023\/05\/11\/plausibility-post-g2-21-apixaban-in-the-uk\/\" data-wpel-link=\"internal\">\u3053\u3061\u3089<\/a>\u3092\u53c2\u7167\uff09\u3002\u79c1\u3068\u3057\u3066\u306f\u3001\u82f1\u56fd\u306e\u5224\u6c7a\u3068\u306f\u53cd\u5bfe\u306e\u7acb\u5834\u3092\u3068\u3063\u305f\u3001\u540c\u3058\u4e8b\u4ef6\u306b\u304a\u3051\u308b\u30d5\u30e9\u30f3\u30b9\u306e\u5224\u6c7a\u306b\u3064\u3044\u3066\u8ad6\u8a55\u3057\u305f\u3044\u3068\u601d\u3044\u307e\u3059\u3002\u4ee5\u4e0b\u306b\u898b\u308b\u3068\u304a\u308a\u3001\u30d5\u30e9\u30f3\u30b9\u306e\u7acb\u5834\u306f\u3001\u3068\u308a\u308f\u3051<strong>\u3082\u3063\u3068\u3082\u3089\u3057\u3055\uff08plausibility\uff09<\/strong>\u306e\u6982\u5ff5\u3068\u512a\u5148\u6a29\u306e\u89e3\u91c8\u3092\u901a\u3058\u3066\u3001\u7279\u306b\u7279\u8a31\u6a29\u8005\u306b\u6709\u5229\u306a\u3082\u306e\u3068\u306a\u3063\u3066\u3044\u307e\u3059\u3002<\/p>\n<p><!-- DA-MAILLAGE DA-CTA-CONTACT --><\/p>\n<div class=\"da-maillage\">\n<p class=\"da-maillage__titre\">\u3055\u3089\u306b\u8a73\u3057\u304f<\/p>\n<ul class=\"da-maillage__liste\">\n<li><a href=\"\/contentieux-des-brevets\/\">\u7279\u8a31\u8a34\u8a1f<\/a><\/li>\n<li><a href=\"\/contact\/\">\u3054\u76f8\u8ac7\u5185\u5bb9\u3092\u304a\u805e\u304b\u305b\u304f\u3060\u3055\u3044<\/a><\/li>\n<\/ul>\n<\/div>\n<p><!-- \/DA-MAILLAGE --><\/p>\n<p><!-- DA-ACF-JA --><\/p>\n<h2>\u4e8b\u5b9f\u95a2\u4fc2<\/h2>\n<p>\u7279\u8a31<a href=\"https:\/\/data.epo.org\/publication-server\/pdf-document?pn=1427415&amp;ki=B1&amp;cc=EP&amp;pd=20090812\">EP1427415<\/a>\uff08\u4ee5\u4e0b\u300cEP\u2019415\u300d\uff09\u306f\u30012001\u5e749\u670821\u65e5\u4ed8\u306e\u7c73\u56fd\u4eee\u51fa\u9858US 60\/324,165\u306b\u57fa\u3065\u304f\u512a\u5148\u6a29\u3092\u4e3b\u5f35\u3057\u3066\u30012002\u5e749\u670817\u65e5\u306b\u56fd\u969b\u51fa\u9858PCT\/US02\/29491\uff08<a href=\"https:\/\/patentscope.wipo.int\/search\/en\/detail.jsf?docId=WO2003026652&amp;tab=PCTBIBLIO&amp;_cid=P21-KTA218-28817-1\">WO 03\/026652<\/a>\uff09\uff08\u4ee5\u4e0b\u300cWO\u2019652\u300d\uff09\u306e\u5f62\u5f0f\u3067\u3001Bristol-Myers Squibb Company\uff08\u4ee5\u4e0b\u300cBMS Company\u300d\uff09\u306e\u540d\u7fa9\u306b\u3088\u308a\u51fa\u9858\u3055\u308c\u307e\u3057\u305f\u3002\u540c\u7279\u8a31\u306f2022\u5e749\u670817\u65e5\u306b\u5b58\u7d9a\u671f\u9593\u304c\u6e80\u4e86\u3057\u3066\u304a\u308a\u30012026\u5e745\u670820\u65e5\u306b\u6e80\u4e86\u3059\u308b\u88dc\u5145\u7684\u4fdd\u8b77\u8a3c\u660e\u66f8\uff08SPC\uff09FR11C0042\u306e\u57fa\u790e\u3068\u306a\u3063\u3066\u3044\u307e\u3059\u3002<\/p>\n<p>EP\u2019415\u306f\u3001\u30a2\u30d4\u30ad\u30b5\u30d0\u30f3\uff08\u8acb\u6c42\u98051\u53ca\u30732\uff09\u3001\u3053\u308c\u3092\u542b\u3080\u533b\u85ac\u7d44\u6210\u7269\uff08\u8acb\u6c42\u98053\u53ca\u30734\uff09\u3001\u6cbb\u7642\u306b\u4f7f\u7528\u3059\u308b\u305f\u3081\u306e\u5f53\u8a72\u5316\u5408\u7269\u53ca\u3073\u533b\u85ac\u7d44\u6210\u7269\u3001\u7279\u306b\u8840\u6813\u585e\u6813\u6027\u75be\u60a3\u306e\u6cbb\u7642\u306e\u305f\u3081\u306e\u3082\u306e\uff08\u8acb\u6c42\u98055\u304b\u308922\uff09\u3001\u3055\u3089\u306b\u4efb\u610f\u3067\u3001\u8840\u6813\u6eb6\u89e3\u6027\u75be\u60a3\u3092\u6cbb\u7642\u3059\u308b\u305f\u3081\u306e\u7b2c\u4e8c\u306e\u6cbb\u7642\u85ac\u3068\u7d44\u307f\u5408\u308f\u305b\u305f\u3082\u306e\uff08\u8acb\u6c42\u980523\u304b\u308929\uff09\u3092\u8acb\u6c42\u3057\u3066\u3044\u307e\u3059\u3002<\/p>\n<p><a href=\"https:\/\/patentblog.kluweriplaw.com\/2023\/07\/25\/apixaban-case-in-france-priority-to-the-patentee\/sans-titre-2\/\"><\/a><\/p>\n<p><strong>\u30a2\u30d4\u30ad\u30b5\u30d0\u30f3<\/strong>\uff081-(4-methoxyphenyl)-7-oxo-6-[4-(2-oxopiperidin-1-yl)phenyl]-4,5,6,7-tetrahydro-1H-pyrazolo[3,4-c]pyridin-3-carbamide\uff09<\/p>\n<p>\u672c\u7279\u8a31\u306b\u5bfe\u3057\u3066\u7570\u8b70\u7533\u7acb\u3066\u306f\u884c\u308f\u308c\u3066\u3044\u307e\u305b\u3093\u3002\u3057\u304b\u3057\u3001\u4e16\u754c\u5404\u5730\u3067\u8907\u6570\u306e\u7121\u52b9\u624b\u7d9a\u304c\u63d0\u8d77\u3055\u308c\u3066\u3044\u307e\u3059\u3002\u4f8b\u3048\u3070\u3001\u30ab\u30ca\u30c0\u7279\u8a31\uff08CA2461202\uff09\u306e\u6709\u52b9\u6027\u306f\u8907\u6570\u306e\u7406\u7531\u3067\u4e89\u308f\u308c\u307e\u3057\u305f\u304c\u3001\u3044\u305a\u308c\u3082\u8a8d\u3081\u3089\u308c\u307e\u305b\u3093\u3067\u3057\u305f\uff08<em>Federal Court judgment of January 12, 2021, in BMS v. Pharmascience &amp; Sandoz<\/em>\uff09\u3002\u3055\u3089\u306b\u3001Sandoz\u3068Teva\u306f\u3001\u7279\u306b\u56fd\u969b\u516c\u958bWO 00\/39131\u306b\u7167\u3089\u3057\u305f\u9032\u6b69\u6027\u306e\u6b20\u5982\u3001\u3082\u3063\u3068\u3082\u3089\u3057\u3055\uff08plausibility\uff09\u306e\u6b20\u5982\u3001\u53ca\u3073\u51fa\u9858\u6642\u306e\u5185\u5bb9\u3092\u8d85\u3048\u308b\u62e1\u5f35\u3092\u7406\u7531\u3068\u3057\u3066\u3001\u672c\u51fa\u9858\u306e\u82f1\u56fd\u90e8\u5206\u306b\u3064\u3044\u3066\u7121\u52b9\u5ba3\u8a00\u3092\u7533\u3057\u7acb\u3066\u307e\u3057\u305f\u3002\u539f\u544a\u306f\u7279\u8a31\u306e\u7121\u52b9\u3092\u52dd\u3061\u53d6\u308a\u307e\u3057\u305f\u3002Arnold\u5224\u4e8b\u306f\u3001\u30a2\u30d4\u30ad\u30b5\u30d0\u30f3\u306e\u69cb\u9020\u306b\u57fa\u3065\u304f\u7406\u8ad6\u3082\u3001\u660e\u7d30\u66f8\u306b\u4f8b\u3068\u3057\u3066\u8a18\u8f09\u3055\u308c\u305f\u30c7\u30fc\u30bf\u3082\u5b58\u5728\u3057\u306a\u3044\u4ee5\u4e0a\u3001\u51fa\u9858\u4e2d\u306e\u3044\u304b\u306a\u308b\u8a18\u8f09\u3082\u3001\u30a2\u30d4\u30ad\u30b5\u30d0\u30f3\u304c\u7b2cXa\u56e0\u5b50\u963b\u5bb3\u5264\u3067\u3042\u308b\u3068\u3044\u3046\u4e3b\u5f35\u3092\u88cf\u4ed8\u3051\u3066\u3044\u306a\u3044\u3068\u5224\u65ad\u3057\u305f\u306e\u3067\u3059\u3002\u3057\u305f\u304c\u3063\u3066\u3001\u5f53\u8a72\u4e3b\u5f35\u306f\u3082\u3063\u3068\u3082\u3089\u3057\u3044\u3068\u306f\u3044\u3048\u307e\u305b\u3093\u3002\u51fa\u9858\u306f\u3001\u5f53\u696d\u8005\u30c1\u30fc\u30e0\u306b\u5bfe\u3057\u3066\u3001\u305d\u306e\u4e3b\u5f35\u304c\u771f\u5b9f\u3067\u3042\u308b\u3068\u5224\u660e\u3059\u308b\u5408\u7406\u7684\u306a\u898b\u8fbc\u307f\u304c\u3042\u308b\u3068\u4fe1\u3058\u308b\u7406\u7531\u3092\u4f55\u3089\u4e0e\u3048\u3066\u3044\u306a\u3044\u304b\u3089\u3067\u3059\u3002<\/p>\n<h2>\u30d5\u30e9\u30f3\u30b9\u5224\u6c7a\u306e\u5185\u5bb9<\/h2>\n<p>\u82f1\u56fd\u306e\u88c1\u5224\u5b98\u3068\u306f\u7570\u306a\u308a\u3001\u30d1\u30ea\u53f8\u6cd5\u88c1\u5224\u6240\u306f\u3001\u9032\u6b69\u6027\u306e\u8a55\u4fa1\u306e\u67a0\u7d44\u307f\u306b\u304a\u3044\u3066\u3001\u30a2\u30d4\u30ad\u30b5\u30d0\u30f3\u304c\u7b2cXa\u56e0\u5b50\u963b\u5bb3\u5264\u3067\u3042\u308b\u3068\u3044\u3046\u4e3b\u5f35\u306f\u3082\u3063\u3068\u3082\u3089\u3057\u3044\u3068\u5224\u65ad\u3057\u307e\u3057\u305f\u3002<\/p>\n<p>\u672c\u4ef6\u306b\u304a\u3044\u3066\u3001\u5f53\u521d\u306e\u51fa\u9858\u306b\u306f\u3001\u4e0a\u8a18\u3067\u5f15\u7528\u3057\u305f\u6bb5\u843d[00028]\u3082\u6bb5\u843d[00180]\u3082\u542b\u307e\u308c\u3066\u304a\u3089\u305a\u3001\u3053\u308c\u3089\u306f\u5be9\u67fb\u6bb5\u968e\u306e2008\u5e74\u3001\u3059\u306a\u308f\u3061\u512a\u5148\u65e5\u3088\u308a\u304b\u306a\u308a\u5f8c\u306b\u8ffd\u52a0\u3055\u308c\u305f\u3082\u306e\u3067\u3057\u305f\u3002\u540c\u69d8\u306b\u3001\u8acb\u6c42\u9805\u3082\u5168\u9762\u7684\u306b\u66f8\u304d\u76f4\u3055\u308c\u3066\u3044\u307e\u3059\u3002\u5f53\u521d\u306e\u8acb\u6c42\u9805\u306f\u3001\u4e2d\u5fc3\u69cb\u9020\u306e\u5468\u56f2\u306b\u3042\u308b\u5404\u7a2e\u7f6e\u63db\u57fa\u306e\u53ef\u80fd\u306a\u5909\u5f62\u306b\u57fa\u3065\u304d\u3001\u975e\u5e38\u306b\u591a\u6570\u306e\u5316\u5408\u7269\uff0874\uff09\u306b\u3064\u3044\u3066\u4fdd\u8b77\u3092\u6c42\u3081\u3066\u3044\u307e\u3057\u305f\u3002\u3053\u306e\u3053\u3068\u304b\u3089\u3001\u51fa\u9858\u4eba\u306f\u51fa\u9858\u6642\u306b\u767a\u660e\u3092\u4fdd\u6709\u3057\u3066\u304a\u3089\u305a\u3001\u7740\u60f3\u3084\u76f4\u611f\u306b\u57fa\u3065\u3044\u3066\u51fa\u9858\u3057\u305f\u3068\u63a8\u8ad6\u3059\u308b\u3053\u3068\u3082\u3067\u304d\u305f\u3067\u3057\u3087\u3046\u3002\u3057\u304b\u3057\u88c1\u5224\u6240\u306f\u3001\u5f53\u521d\u306eWO\u2019652\u51fa\u9858\u304c\u30a2\u30d4\u30ad\u30b5\u30d0\u30f3\u3092\u5177\u4f53\u7684\u306b\u958b\u793a\u3057\u3066\u304a\u308a\u3001\u3055\u3089\u306b\u5b9f\u65bd\u4f8b\uff08\u7b2c18\u53f7\uff09\u3068\u3057\u3066\u4f8b\u793a\u3057\u3066\u3044\u308b\u3053\u3068\u3092\u6307\u6458\u3057\u307e\u3059\u3002\u78ba\u304b\u306b\u305d\u308c\u306f\u3001140\u306e\u5b9f\u65bd\u4f8b\u3068100\u3092\u8d85\u3048\u308b\u5316\u5408\u7269\u306e\u5408\u6210\u306e\u8a18\u8f09\u306e\u4e2d\u306e\u4e00\u3064\u306b\u3059\u304e\u307e\u305b\u3093\u3002\u305d\u3046\u3067\u3042\u308b\u3068\u3057\u3066\u3082\u3001\u88c1\u5224\u6240\u306f\u3001\u3053\u306eWO\u2019652\u6587\u66f8\u304c\u8a66\u9a13\u3092\u958b\u793a\u3057\u3066\u304a\u308a\u3001\u305d\u306e\u7d50\u679c\u3001\u975e\u5e38\u306b\u826f\u597d\u306a\u89aa\u548c\u6027\u3001\u7279\u306bKi # 0.001 \u03bcM\u3092\u6709\u3059\u308b\u300c\u6700\u3082\u597d\u307e\u3057\u3044\u300d\u5316\u5408\u7269\u304c\u7279\u5b9a\u3055\u308c\u3066\u3044\u308b\u3053\u3068\u3092\u6307\u6458\u3057\u307e\u3059\u3002WO\u2019652\u306f\u3055\u3089\u306b\u3001\u672c\u767a\u660e\u304c\u3001\u6539\u5584\u3055\u308c\u305f\u85ac\u7406\u5b66\u7684\u53ca\u3073\u85ac\u7269\u52d5\u614b\u5b66\u7684\u7279\u6027\u3092\u6709\u3059\u308b\u7b2cXa\u56e0\u5b50\u963b\u5bb3\u5264\u306b\u95a2\u3059\u308b\u3082\u306e\u3067\u3042\u308b\u3068\u8ff0\u3079\u3066\u3044\u307e\u3059\u3002\u307e\u305f\u30013.07 g\u306e\u30a2\u30d4\u30ad\u30b5\u30d0\u30f3\u304c\u5408\u6210\u3055\u308c\u305f\u3053\u3068\u3082\u8a18\u8f09\u3055\u308c\u3066\u3044\u307e\u3059\uff08178\u9801\uff09\u3002\u3053\u306e\u91cf\u306f\u3001\u660e\u7d30\u66f8\u306b\u3088\u308c\u3070\u7fa4\u3092\u629c\u3044\u3066\u6700\u5927\u306e\u5408\u6210\u91cf\u3067\u3042\u308b\u3068\u3044\u3046\u70b9\u3067\u3001\u30a2\u30d4\u30ad\u30b5\u30d0\u30f3\u3092\u4ed6\u306e\u3059\u3079\u3066\u306e\u5408\u6210\u5316\u5408\u7269\u306e\u5b9f\u65bd\u4f8b\u304b\u3089\u7591\u3044\u306a\u304f\u533a\u5225\u3059\u308b\u3082\u306e\u3067\u3059\uff081\u30b0\u30e9\u30e0\u306b\u9054\u3059\u308b\u5b9f\u65bd\u4f8b\u306f\u4ed6\u306b\u306a\u304f\u3001\u6b21\u306b\u591a\u3044\u5408\u6210\u91cf\u306f\u5b9f\u65bd\u4f8b91\u306e0.34 g\u3067\u3059\uff09\u3002\u5f53\u696d\u8005\u3067\u3042\u308c\u3070\u3001\u6280\u8853\u5e38\u8b58\u306b\u57fa\u3065\u304d\u3001\u7279\u8a31\u6a29\u8005\u304c\u30a2\u30d4\u30ad\u30b5\u30d0\u30f3\u3092\u6709\u671b\u306a\u5316\u5408\u7269\u3001\u3055\u3089\u306b\u306f\u6700\u3082\u6709\u671b\u306a\u5316\u5408\u7269\u3068\u8003\u3048\u3066\u3044\u305f\u3053\u3068\u3092\u5fc5\u7136\u7684\u306b\u63a8\u8ad6\u3057\u305f\u306f\u305a\u3067\u3059\u3002<\/p>\n<p>\u3055\u3089\u306b\u3001BMS\u306f\u3001WO\u2019652\u51fa\u9858\u3088\u308a\u524d\u306b\u4f5c\u6210\u3055\u308c\u305f\u7814\u7a76\u8005\u306e\u5b9f\u9a13\u30ce\u30fc\u30c8\u53ca\u3073\u5831\u544a\u66f8\u3092\u63d0\u51fa\u3057\u307e\u3057\u305f\u3002\u3053\u308c\u3089\u306f\u3001BMS\u304c\u767a\u660e\u3001\u3059\u306a\u308f\u3061\u8840\u6813\u585e\u6813\u6027\u75be\u60a3\u306e\u6cbb\u7642\u306b\u6709\u7528\u3067\u3001\u6539\u5584\u3055\u308c\u305f\u85ac\u7406\u5b66\u7684\u53ca\u3073\u85ac\u7269\u52d5\u614b\u5b66\u7684\u7279\u6027\u3092\u6709\u3059\u308b\u7b2cXa\u56e0\u5b50\u963b\u5bb3\u5264\u3092\u4fdd\u6709\u3057\u3066\u3044\u305f\u3053\u3068\u3092\u4e89\u3046\u4f59\u5730\u306a\u304f\u8a3c\u660e\u3059\u308b\u3082\u306e\u3067\u3042\u308a\u3001\u3057\u304b\u3082\u771f\u5263\u306b\u4e89\u308f\u308c\u3066\u3082\u3044\u307e\u305b\u3093\u3002\u3053\u308c\u3089\u306e\u8981\u7d20\u306f\u3001BMS\u304c\u8aac\u660e\u3057\u305f\u7814\u7a76\u8a08\u753b\u3001\u53ca\u3073\u512a\u5148\u65e5\u524d\u306bPinto\u535a\u58eb\u3068\u305d\u306e\u540c\u50da\u304c\u30a2\u30d4\u30ad\u30b5\u30d0\u30f3\u3092\u767a\u898b\u3057\u305f\u3053\u3068\u3092\u5b8c\u5168\u306b\u88cf\u4ed8\u3051\u3066\u3044\u307e\u3059\u3002<\/p>\n<p>\u88c1\u5224\u6240\u306f\u3001\u51fa\u9858\u6642\u306b\u304a\u3051\u308bEP\u2019415\u306e\u5148\u884c\u6280\u8853\u3078\u306e\u8ca2\u732e\u306e\u300c\u3082\u3063\u3068\u3082\u3089\u3057\u3055\u300d\u53c8\u306f\u300c\u4fe1\u6191\u6027\u300d\u306e\u6b20\u5982\u3001\u3072\u3044\u3066\u306f\u8acb\u6c42\u98051\u304b\u30894\u306e\u9032\u6b69\u6027\u306e\u6b20\u5982\u3092\u4e3b\u5f35\u3059\u308b\u6297\u5f01\u306f\u3001\u3057\u305f\u304c\u3063\u3066\u9000\u3051\u3089\u308c\u308b\u3068\u7d50\u8ad6\u3065\u3051\u307e\u3057\u305f\u3002<\/p>\n<p>\u3055\u3089\u306b\u3001\u512a\u5148\u6a29\u306b\u95a2\u3057\u3066\u3001\u88c1\u5224\u6240\u306f\u6b21\u306e\u3088\u3046\u306b\u6307\u6458\u3057\u307e\u3059\u3002BMS Pharma\uff08WO\u2019652\u3092\u51fa\u9858\u3057\u305fBMS Company\u3067\u306f\u3042\u308a\u307e\u305b\u3093\uff09\u306e\u8cc7\u7523\u3067\u3042\u3063\u305f\u4eee\u51fa\u9858US 60\/324,165\u306b\u7531\u6765\u3059\u308b\u512a\u5148\u6a29\u306e\u8b72\u6e21\u306f\u3001\u539f\u5247\u3068\u3057\u3066\u30012001\u5e7411\u67083\u65e5\uff08\u767a\u660e\u8005\u304cBMS Pharma\u306b\u767a\u660e\u3092\u8b72\u6e21\u3057\u305f\u65e5\uff09\u304b\u3089PCT\u51fa\u9858\u306e\u51fa\u9858\u65e5\u3067\u3042\u308b2002\u5e749\u670817\u65e5\u307e\u3067\u306e\u9593\u306b\u3001\u66f8\u9762\u306b\u3088\u308aBMS Company\u306b\u5bfe\u3057\u3066\u884c\u308f\u308c\u308b\u3079\u304d\u3067\u3057\u305f\u3002\u305d\u3046\u3057\u3066\u521d\u3081\u3066\u3001BMS Company\u306f\u30d1\u30ea\u6761\u7d04\u306e\u610f\u5473\u306b\u304a\u3051\u308bBMS Pharma\u306e\u627f\u7d99\u4eba\u3068\u307f\u306a\u3055\u308c\u3001\u512a\u5148\u6a29\u3092\u6709\u52b9\u306b\u884c\u4f7f\u3057\u305f\u3068\u307f\u306a\u3055\u308c\u5f97\u305f\u306e\u3067\u3059\u3002<\/p>\n<p>\u3057\u304b\u3057\u3001\u30d5\u30e9\u30f3\u30b9\u306e\u88c1\u5224\u5b98\u306f\u3001Holland\u5224\u4e8b\u306e\u9673\u8ff0\u306b\u8a00\u53ca\u3057\u3066\u3044\u307e\u3059\u3002\u540c\u5224\u4e8b\u306f\u3001\u4f1a\u793e\u9593\u306e\u53b3\u683c\u306a\u533a\u5225\u306b\u95a2\u3059\u308b\u3053\u306e\u300c\u4e8c\u5143\u7684\u300d\u306a\u7d50\u8ad6\u306b\u7559\u4fdd\u3092\u4ed8\u3051\u3001\u4e00\u5b9a\u306e\u5834\u5408\u306b\u306f\u3001\u30c7\u30e9\u30a6\u30a7\u30a2\u5dde\u6cd5\uff08BMS Pharma\u3068BMS Company\u306f\u3044\u305a\u308c\u3082\u540c\u5dde\u3067\u8a2d\u7acb\u3055\u308c\u3066\u3044\u307e\u3059\uff09\u304c\u300c\u6cd5\u4eba\u683c\u306e\u30f4\u30a7\u30fc\u30eb\u3092\u5f15\u304d\u4e0a\u3052\u308b\u300d\u3053\u3068\u3092\u8a8d\u3081\u3066\u3044\u308b\u3068\u8ff0\u3079\u3066\u304a\u308a\u3001\u3053\u308c\u306f\u8a3c\u660e\u66f8\u306b\u3088\u308b\u3082\u306e\u3067\u3001Chandler\u5224\u4e8b\u306e\u8a3c\u8a00\u306b\u3088\u3063\u3066\u3082\u78ba\u8a8d\u3055\u308c\u3066\u3044\u307e\u3059\u3002\u672c\u4ef6\u3067\u306f\u3001BMS Pharma\u306fBMS Company\u306e\u5b8c\u5168\u5b50\u4f1a\u793e\u3067\u3042\u308a\u3001\u7279\u8a31\u30dd\u30fc\u30c8\u30d5\u30a9\u30ea\u30aa\u306e\u7ba1\u7406\u306f\u3082\u3063\u3071\u3089BMS Company\u304c\u305d\u306e\u5358\u72ec\u306e\u5229\u76ca\u306b\u304a\u3044\u3066\u6c7a\u5b9a\u3057\u3066\u3044\u307e\u3057\u305f\u3002\u305d\u306e\u7d50\u679c\u3001\u88c1\u5224\u6240\u306f\u3001\u512a\u5148\u6a29\u306f\u66f8\u9762\u306a\u3057\u306b\u8b72\u6e21\u3055\u308c\u3066\u3044\u305f\u3068\u5224\u65ad\u3057\u307e\u3057\u305f\u3002<\/p>\n<h2>\u30d5\u30e9\u30f3\u30b9\u5224\u6c7a\u306e\u5c04\u7a0b<\/h2>\n<p>\u79c1\u898b\u3067\u306f\u3001\u672c\u5224\u6c7a\u306e\u4e8c\u3064\u306e\u5074\u9762\u3001\u3059\u306a\u308f\u3061\u3082\u3063\u3068\u3082\u3089\u3057\u3055\u3068\u512a\u5148\u6a29\u304c\u7279\u306b\u8208\u5473\u6df1\u3044\u3068\u8003\u3048\u307e\u3059\u3002<\/p>\n<p>\u30d5\u30e9\u30f3\u30b9\u306e\u5224\u4f8b\u306b\u306f\u3001\u3082\u3063\u3068\u3082\u3089\u3057\u3055\u306e\u6982\u5ff5\u3092\u9069\u7528\u3057\u305f\u4f8b\u304c\u6570\u591a\u304f\u3042\u308a\u307e\u3059\u3002\u4f8b\u3048\u3070\u3001\u767a\u660e\u306f\u51fa\u9858\u65e5\u306b\u304a\u3044\u3066\u300c\u4fe1\u6191\u6027\u306e\u3042\u308b\u300d\u53c8\u306f\u300c\u3082\u3063\u3068\u3082\u3089\u3057\u3044\u300d\u6280\u8853\u7684\u52b9\u679c\u3092\u6709\u3057\u3066\u3044\u306a\u3051\u308c\u3070\u306a\u3089\u305a\u3001\u305d\u306e\u6b20\u5982\u306f\u9032\u6b69\u6027\u306e\u6b20\u5982\u3092\u7406\u7531\u3068\u3057\u3066\u5236\u88c1\u3055\u308c\u308b\u3068\u3001\u3059\u3067\u306b\u5224\u793a\u3055\u308c\u3066\u3044\u307e\u3059\uff08\u4f8b\u3048\u3070\u3001<em>TGI Paris, October 6, 2009, RG n\u00b007\/16446, Teva v. Sepracor<\/em>\uff09\u3002\u307e\u305f\u3001\u6280\u8853\u7684\u52b9\u679c\u306e\u4fe1\u6191\u6027\u306f\u3001\u512a\u5148\u65e5\u53c8\u306f\u51fa\u9858\u65e5\u306b\u304a\u3044\u3066\uff08\u4f8b\u3048\u3070\u3001<em>TGI Paris, October 6, 2009, RG n\u00b007\/16446, Teva v. Sepracor<\/em>\uff09\u3001\u7279\u8a31\u6a29\u8005\u306e\u4e3b\u5f35\u3092\u542b\u3080\u51fa\u9858\u4e2d\u306e\u8981\u7d20\u306b\u7167\u3089\u3057\u3066\u8a55\u4fa1\u3055\u308c\u3001\u7279\u8a31\u6a29\u8005\u306f\u51fa\u9858\u306b\u304a\u3044\u3066\u8a66\u9a13\u3084\u6cbb\u9a13\u306e\u7d50\u679c\u305d\u306e\u4ed6\u306e\u30c7\u30fc\u30bf\u3092\u63d0\u4f9b\u3059\u308b\u7fa9\u52d9\u3092\u8ca0\u308f\u306a\u3044\u3068\u3082\u5224\u793a\u3055\u308c\u3066\u3044\u307e\u3059\uff08\u4f8b\u3048\u3070\u3001<em>CA Paris, October 29, 2020, RG n\u00b0126\/2019, Ethypharm v. Merck Sharp &amp; Dohme Corp<\/em>\uff09\u3002\u51fa\u9858\u5f8c\u306e\u8981\u7d20\u3082\u8003\u616e\u3055\u308c\u5f97\u307e\u3059\u304c\u3001\u6280\u8853\u7684\u52b9\u679c\u306e\u4fe1\u6191\u6027\u3092\u8a3c\u660e\u3059\u308b\u552f\u4e00\u306e\u6839\u62e0\u3068\u3059\u308b\u3053\u3068\u306f\u3067\u304d\u307e\u305b\u3093\uff08\u4f8b\u3048\u3070\u3001<em>TGI Paris, October 6, 2009, RG n\u00b007\/16446, Teva v. Sepracor<\/em>\uff09\u3002<\/p>\n<p>\u672c\u5224\u6c7a\u306f\u3001\u6280\u8853\u7684\u52b9\u679c\u306f\u8a66\u9a13\u3084\u30c7\u30fc\u30bf\u306e\u63d0\u4f9b\u3092\u8981\u3059\u308b\u3053\u3068\u306a\u304f\u3082\u3063\u3068\u3082\u3089\u3057\u3044\u3082\u306e\u3067\u3042\u308a\u5f97\u308b\u3053\u3068\u3092\u660e\u78ba\u306b\u3057\u3066\u3044\u307e\u3059\u3002\u3053\u308c\u306f\u307e\u3055\u306b\u3001\u82f1\u56fd\u3067Arnold\u5224\u4e8b\u304c\u5224\u65ad\u3057\u305f\u3053\u3068\u306e\u6b63\u53cd\u5bfe\u3067\u3059\u3002\u3057\u304b\u3057\u3001\u3053\u306e\u67d4\u8edf\u6027\u306f\u6b27\u5dde\u7279\u8a31\u5e81\uff08EPO\uff09\u62e1\u5927\u5be9\u5224\u90e8\u306eG 2\/21\u6c7a\u5b9a\u306b\u6cbf\u3046\u3082\u306e\u3067\u3059\u3002\u305d\u308c\u306f\u5f53\u521d\u304b\u3089\u306e\uff08ab initio\uff09\u975e\u3082\u3063\u3068\u3082\u3089\u3057\u3055\u306e\u627f\u8a8d\u3067\u3042\u308b\u3088\u3046\u306b\u601d\u308f\u308c\u307e\u3059\u3002\u3059\u306a\u308f\u3061\u3001\u51fa\u9858\u65e5\u5f8c\u306e\u8a3c\u62e0\u306f\u3001\u5f53\u696d\u8005\u304c\u51fa\u9858\u65e5\u306b\u304a\u3044\u3066\u6280\u8853\u7684\u52b9\u679c\u304c\u5f97\u3089\u308c\u308b\u3053\u3068\u3092\u7591\u3046\u6b63\u5f53\u306a\u7406\u7531\u3092\u6709\u3057\u3066\u3044\u305f\u5834\u5408\u306b\u306e\u307f\u8003\u616e\u304b\u3089\u9664\u5916\u3055\u308c\u5f97\u308b\u3068\u3044\u3046\u3053\u3068\u3067\u3059\uff08\u4f8b\u3048\u3070\u3001<em>T919\/15, T578\/06, T2015\/20<\/em>\uff09\u3002\u88c1\u5224\u6240\u306f\u3055\u3089\u306b\u3001\u5f53\u696d\u8005\u304c\u767a\u660e\u3092\u7406\u89e3\u3057\u3001\u305d\u308c\u304c\u300c\u3082\u3063\u3068\u3082\u3089\u3057\u3044\u300d\uff08\u304b\u3064\u5341\u5206\u306b\u958b\u793a\u3055\u308c\u3066\u3044\u308b\uff09\u3068\u307f\u306a\u3055\u308c\u308b\u3088\u3046\u3001\u7279\u8a31\u6a29\u8005\u306f\u7279\u306b\u8a66\u9a13\u306b\u3088\u3063\u3066\u8acb\u6c42\u3055\u308c\u305f\u65b0\u305f\u306a\u52b9\u679c\u3092\u8a18\u8f09\u3059\u308b\u3053\u3068\u304c\u671f\u5f85\u3055\u308c\u308b\u3082\u306e\u306e\u3001\u305d\u308c\u306f\u7279\u8a31\u304c\u7269\u8cea\u53c8\u306f\u7d44\u6210\u7269\u306e\u305d\u306e\u5f8c\u306e\u6cbb\u7642\u7528\u9014\u306b\u95a2\u3059\u308b\u5834\u5408\u306b\u9650\u3089\u308c\u308b\u3068\u660e\u793a\u3057\u3066\u3044\u307e\u3059\uff08\u4f8b\u3048\u3070\u3001<em>Cass. Com., December 6, 2017, n\u00b0 15-19.72<\/em>6\uff09\u3002<\/p>\n<p>\u512a\u5148\u6a29\u306e\u8b72\u6e21\u306b\u95a2\u3057\u3066\u306f\u3001\u5224\u4f8b\u306b\u3088\u308c\u3070\u3001\u6700\u521d\u306e\u51fa\u9858\u306e\u8b72\u6e21\u306f\u5f53\u7136\u306b\u512a\u5148\u6a29\u306e\u8b72\u6e21\u3092\u4f34\u3046\u3082\u306e\u3067\u306f\u3042\u308a\u307e\u305b\u3093\u3002\u7834\u6bc0\u9662\u306b\u3088\u308c\u3070\u3001\u512a\u5148\u6a29\u306f<em>\u300c\u6700\u521d\u306e\u7279\u8a31\u51fa\u9858\u306b\u3088\u3063\u3066\u4ed8\u4e0e\u3055\u308c\u308b\u6a29\u5229\u3068\u306f\u5225\u500b\u304b\u3064\u72ec\u7acb\u306e\u6a29\u5229<\/em>\u300d<em>\u3092\u69cb\u6210\u3057\u307e\u3059\u3002<\/em>\u305d\u306e\u305f\u3081\u3001\u3053\u306e\u6a29\u5229\u306e\u8b72\u6e21\u306b\u306f\u7279\u8a31\u8b72\u6e21\u5951\u7d04\u306b\u660e\u793a\u306e\u6761\u9805\u3092\u542b\u3081\u308b\u3053\u3068\u304c\u5fc5\u8981\u3067\u3042\u308a\u3001\u300c<em>\u4e00\u5207\u306e\u7559\u4fdd\u53c8\u306f\u4f8b\u5916\u306a\u304f\u3001\u3053\u308c\u306b\u4ed8\u968f\u3059\u308b\u3059\u3079\u3066\u306e\u6a29\u5229\u3068\u3068\u3082\u306b<\/em>\u300d<em>\u3068\u3044\u3046\u5358\u306a\u308b\u8a18\u8f09\u304b\u3089\u751f\u3058\u308b\u3053\u3068\u306f\u3042\u308a\u307e\u305b\u3093\u3002<\/em>\u3053\u306e\u70b9\u306b\u3064\u3044\u3066\u30d1\u30ea\u53f8\u6cd5\u88c1\u5224\u6240\u304c\u63a1\u7528\u3057\u305f\u7acb\u5834\u306f\u3001\u3082\u3063\u3068\u3082\u3089\u3057\u3055\u306b\u95a2\u3059\u308b\u5224\u793a\u306e\u9670\u306b\u3084\u3084\u96a0\u308c\u3066\u3044\u308b\u3082\u306e\u306e\u3001\u91cd\u8981\u3067\u3042\u308a\u3001\u5f93\u6765\u306e\u5224\u4f8b\u3068\u77db\u76fe\u3059\u308b\u3082\u306e\u3067\u3059\u3002<\/p>\n<h2>\u82e5\u5e72\u306e\u8003\u5bdf<\/h2>\n<p>\u7b2c\u4e00\u306b\u3001\u3082\u3063\u3068\u3082\u3089\u3057\u3055\u306b\u95a2\u3057\u3066\u3001\u672c\u4ef6\u3067\u306f\u3001\u56fd\u969b\u51fa\u9858<a href=\"https:\/\/patentscope.wipo.int\/search\/en\/detail.jsf?docId=WO2000039131&amp;_cid=P21-KTA3F8-44812-1\">WO 00\/39131<\/a>\u304c\u30a2\u30d4\u30ad\u30b5\u30d0\u30f3\u306b\u69cb\u9020\u7684\u306b\u8fd1\u3044\u5316\u5408\u7269\uff08\u4f8b\u3048\u3070\u3001G = 4-(methoxy)phenyl\u306e\u5834\u5408\u306b207\u9801\u306e\u8868I\u306e\u7b2c\u4e00\u306e\u4e00\u822c\u5f0f\u306b\u5f53\u3066\u306f\u3081\u305f240\u9801\u306e\u5316\u5408\u72691041\u304b\u30891053\u3092\u53c2\u7167\uff09\u306b\u95a2\u3059\u308b\u3082\u306e\u3067\u3042\u308a\u3001\u305d\u308c\u3089\u304c\u8840\u6813\u585e\u6813\u6027\u75be\u60a3\u306e\u6cbb\u7642\u306b\u6709\u7528\u306a\u7b2cXa\u56e0\u5b50\u963b\u5bb3\u5264\u3068\u3057\u3066\u63d0\u793a\u3055\u308c\u3066\u3044\u305f\u3053\u3068\u3092\u60f3\u8d77\u3059\u3079\u304d\u3067\u3059\u3002\u3057\u305f\u304c\u3063\u3066\u3001\u3053\u306e\u51fa\u9858\u306f\u3001\u8ab2\u984c\u89e3\u6c7a\u30a2\u30d7\u30ed\u30fc\u30c1\u306e\u9069\u7528\u306b\u9069\u3057\u305f\u6700\u3082\u8fd1\u3044\u5148\u884c\u6280\u8853\u3092\u69cb\u6210\u3057\u307e\u3059\u3002\u30a2\u30d4\u30ad\u30b5\u30d0\u30f3\u3068WO 00\/39131\u306b\u8a18\u8f09\u3055\u308c\u305f\u5316\u5408\u7269\u3068\u306e\u69cb\u9020\u4e0a\u306e\u76f8\u9055\u306b\u306f\u3001\u7279\u6bb5\u306e\u6280\u8853\u7684\u52b9\u679c\u306f\u7d50\u3073\u4ed8\u3051\u3089\u308c\u3066\u3044\u307e\u305b\u3093\u3067\u3057\u305f\u3002\u3057\u305f\u304c\u3063\u3066\u3001\u5ba2\u89b3\u7684\u6280\u8853\u8ab2\u984c\u306f\u3001\u56fd\u969b\u51fa\u9858WO 00\/39131\u306b\u8a18\u8f09\u3055\u308c\u305f\u3082\u306e\u306e\u4ee3\u66ff\u3068\u3057\u3066\u3001\u8840\u6813\u585e\u6813\u6027\u75be\u60a3\u306e\u6cbb\u7642\u306b\u6709\u7528\u306a\u7b2cXa\u56e0\u5b50\u963b\u5bb3\u5264\u3092\u898b\u51fa\u3059\u3053\u3068\u3068\u5b9a\u5f0f\u5316\u3057\u5f97\u305f\u306e\u3067\u3059\u3002\u5f53\u8a72\u5316\u5408\u7269\u3001\u7279\u306b\u30a2\u30d4\u30ad\u30b5\u30d0\u30f3\u304c\u6cbb\u7642\u52b9\u679c\u306e\u57fa\u790e\u3068\u306a\u308b\u52b9\u679c\u3092\u6709\u3059\u308b\u3053\u3068\u3092\u793a\u3059\u5b9f\u9a13\u30c7\u30fc\u30bf\u306f\u3001\u7279\u8a31\u4e2d\u306b\u4f55\u3089\u793a\u3055\u308c\u3066\u3044\u307e\u305b\u3093\u3067\u3057\u305f\u3002<\/p>\n<p>\u672c\u4ef6\u306b\u304a\u3044\u3066\u3082\u3063\u3068\u3082\u3089\u3057\u3055\u3092\u8a8d\u3081\u308b\u3053\u3068\u306b\u3088\u308a\u3001\u7b2c\u4e00\u5be9\u88c1\u5224\u6240\u306f\u3082\u3063\u3068\u3082\u3089\u3057\u3055\u306b\u3064\u3044\u3066\u67d4\u8edf\u306a\u89e3\u91c8\u3092\u63a1\u7528\u3057\u3066\u3044\u307e\u3059\u3002\u3053\u3046\u3057\u3066\u672c\u5224\u6c7a\u306fEPO\u306e<a href=\"https:\/\/patentblog.kluweriplaw.com\/2023\/03\/29\/plausibility-in-g2-21-has-the-elephant-left-the-room\/\">G 2\/21<\/a>\u6c7a\u5b9a\u306b\u6cbf\u3046\u3082\u306e\u3067\u3059\u304c\u3001\u305d\u308c\u306f<em>ab initio<\/em>\u306e\u975e\u3082\u3063\u3068\u3082\u3089\u3057\u3055\u3068\u3044\u3046\u3001\u3088\u308a\u6709\u5229\u306a\u7acb\u5834\u3092\u63a1\u7528\u3059\u308b\u3053\u3068\u306b\u3088\u308b\u3082\u306e\u3067\u3042\u308a\u3001\u4ed6\u65b9\u3067\u82f1\u56fd\u306e\u88c1\u5224\u5b98\u306e\u89e3\u91c8\u3068\u306f\u76f8\u53cd\u3059\u308b\u89e3\u91c8\u3092\u793a\u3057\u3066\u3044\u307e\u3059\u3002\u82f1\u56fd\u306e\u88c1\u5224\u5b98\u306f\u8a66\u9a13\u3068\u30c7\u30fc\u30bf\u304c\u5fc5\u9808\u3067\u3042\u308b\u3068\u8003\u3048\u308b\u306e\u306b\u5bfe\u3057\u3001\u30d5\u30e9\u30f3\u30b9\u306e\u88c1\u5224\u5b98\u306f\u9006\u306b\u3001\u305d\u306e\u5f8c\u306e\u6cbb\u7642\u7528\u9014\u3068\u3044\u3046\u7279\u5b9a\u306e\u5834\u5408\u3092\u9664\u304d\u3001\u305d\u308c\u3089\u306f\u5fc5\u9808\u3067\u306f\u306a\u3044\u3068\u8003\u3048\u3066\u3044\u308b\u306e\u3067\u3059\u3002<\/p>\n<p>\u3053\u306e\u7acb\u5834\u306f\u3001\u3082\u3063\u3068\u3082\u3089\u3057\u3055\u306e\u57fa\u6e96\u3092\u7279\u306b\u4f4e\u3044\u6c34\u6e96\u306b\u8a2d\u5b9a\u3059\u308b\u50be\u5411\u306b\u3042\u308a\u3001\u305d\u308c\u304c\u7279\u8a31\u6a29\u8005\u306b\u3068\u3063\u3066\u6709\u5229\u3067\u3042\u308b\u3053\u3068\u306f\u7591\u3044\u3042\u308a\u307e\u305b\u3093\u3002\u305d\u308c\u81ea\u4f53\u3068\u3057\u3066\u3001\u3053\u306e\u89e3\u91c8\u306f\u4e00\u822c\u7684\u306a\u50be\u5411\u306e\u4e00\u90e8\u3092\u306a\u3059\u9650\u308a\u306b\u304a\u3044\u3066\u885d\u6483\u7684\u306a\u3082\u306e\u3067\u306f\u3042\u308a\u307e\u305b\u3093\u3002\u3057\u304b\u3057\u3001\u3042\u308b\u5224\u6c7a\u304c\u4e00\u822c\u7684\u306a\u50be\u5411\u306b\u6cbf\u3063\u3066\u3044\u308b\u304b\u3089\u3068\u3044\u3063\u3066\u3001\u305d\u308c\u306b\u8cdb\u540c\u3059\u3079\u304d\u3053\u3068\u306b\u306f\u306a\u308a\u307e\u305b\u3093\u3002\u672c\u4ef6\u306b\u304a\u3044\u3066\u3001\u3082\u3063\u3068\u3082\u3089\u3057\u3055\u306e\u6d3b\u7528\u306f\u3001\u8acb\u6c42\u3055\u308c\u305f\u767a\u660e\u306b\u3088\u3063\u3066\u9054\u6210\u3055\u308c\u308b\u7d50\u679c\u306e\u5076\u7136\u6027\u306b\u7279\u5fb4\u3065\u3051\u3089\u308c\u308b\u5206\u91ce\u3001\u3059\u306a\u308f\u3061\u533b\u85ac\u5206\u91ce\u306b\u304a\u3044\u3066\u3001\u7279\u8a31\u6027\u306e\u8a55\u4fa1\u3092\u5bb9\u6613\u306b\u3059\u308b\u3053\u3068\u3092\u610f\u56f3\u3057\u3066\u3044\u308b\u3088\u3046\u306b\u79c1\u306b\u306f\u601d\u308f\u308c\u307e\u3059\u3002\u3057\u304b\u3057\u3001\u305d\u308c\u81ea\u4f53\u3059\u3067\u306b\u672c\u8cea\u7684\u306b\u51fa\u9858\u4eba\u306b\u6709\u5229\u306a\u3053\u306e\u57fa\u6e96\u306e\u8a55\u4fa1\u3092\u3001\u904e\u5ea6\u306b\u5f15\u304d\u4e0b\u3052\u308b\u3053\u3068\u306b\u306f\u614e\u91cd\u3067\u3042\u308b\u3079\u304d\u3067\u3059\u3002\u305d\u3046\u3067\u306a\u3051\u308c\u3070\u3001\u6280\u8853\u306e\u9818\u57df\u3068\u3044\u3046\u3088\u308a\u3080\u3057\u308d\u7814\u7a76\u306e\u9818\u57df\u306b\u5c5e\u3059\u308b\u50be\u5411\u306e\u3042\u308b\u767a\u660e\u306e\u5b9f\u65bd\u3092\u81ea\u3089\u306b\u7559\u4fdd\u3057\u5f97\u308b\u51fa\u9858\u4eba\u306b\u3001\u4e0d\u5f53\u306a\u5229\u76ca\u3092\u4e0e\u3048\u308b\u3053\u3068\u306b\u306a\u308a\u307e\u3059\u3002\u8981\u3059\u308b\u306b\u3001\u3082\u3063\u3068\u3082\u3089\u3057\u3055\u304c\u5426\u5b9a\u3055\u308c\u308b\u306e\u306f\u3001\u5f53\u696d\u8005\u304c\u51fa\u9858\u6642\u306b\u7591\u3046\u6b63\u5f53\u306a\u7406\u7531\u3092\u6709\u3057\u3066\u3044\u305f\u5834\u5408\u306b\u9650\u3089\u308c\u308b\u3053\u3068\u306b\u306a\u308a\u3001\u305d\u306e\u7d50\u679c\u3001\u51fa\u9858\u4eba\u306f\u3001\u307e\u3060\u7740\u624b\u3059\u3089\u3057\u3066\u3044\u306a\u3044\u7814\u7a76\u5206\u91ce\u5168\u4f53\u3092\u81ea\u3089\u306e\u3082\u306e\u3068\u3057\u3066\u8acb\u6c42\u3067\u304d\u308b\u3053\u3068\u306b\u306a\u308b\u306e\u3067\u3059\u3002<\/p>\n<p>\u307e\u305f\u3001\u88c1\u5224\u6240\u304c\u6280\u8853\u7684\u8ca2\u732e\u3001\u5177\u4f53\u7684\u7d50\u679c\u53ca\u3073\u6280\u8853\u7684\u7d50\u679c\u3092\u6df7\u540c\u3057\u3066\u3044\u308b\u3053\u3068\u306b\u3082\u7559\u610f\u3059\u3079\u304d\u3067\u3059\u3002\u6280\u8853\u7684\u8ca2\u732e\u306f\u6280\u8853\u7684\u52b9\u679c\u306b\u3042\u308b\u306e\u3067\u306f\u306a\u304f\u3001\u5148\u884c\u6280\u8853\u306b\u5bfe\u3059\u308b\u767a\u660e\u306e\u8ca2\u732e\u306b\u3042\u308a\u307e\u3059\u3002\u6280\u8853\u7684\u7d50\u679c\u306f\u5177\u4f53\u7684\u7d50\u679c\u3068\u533a\u5225\u3057\u5f97\u308b\u3082\u306e\u3067\u3059\u3002\u3082\u3063\u3068\u3082\u3001\u79c1\u81ea\u8eab\u306f\u3053\u306e\u70b9\u3092\u975e\u5e38\u306b\u6df1\u304f\u7591\u3063\u3066\u3044\u307e\u3059\u304c\u3001\u3044\u305a\u308c\u306b\u305b\u3088\u3001\u672c\u4ef6\u306b\u304a\u3044\u3066\u6280\u8853\u7684\u7d50\u679c\u3092\u7279\u5fb4\u3065\u3051\u308b\u3082\u306e\u304c\u4f55\u3067\u3042\u308b\u304b\u3092\u660e\u3089\u304b\u306b\u3059\u308b\u5fc5\u8981\u304c\u3042\u3063\u305f\u306f\u305a\u3067\u3042\u308a\u3001\u88c1\u5224\u6240\u306f\u672c\u4ef6\u306b\u304a\u3044\u3066\u305d\u308c\u3092\u884c\u3063\u3066\u3044\u307e\u305b\u3093\u3002<\/p>\n<p>\u512a\u5148\u6a29\u306b\u95a2\u3057\u3066\u306f\u3001\u79c1\u306f\u3088\u308a\u5f37\u3044\u9a5a\u304d\u3068\u6279\u5224\u3092\u899a\u3048\u307e\u3059\u3002\u3053\u3053\u3067\u3082\u3001\u63a1\u7528\u3055\u308c\u305f\u7acb\u5834\u306f\u7279\u8a31\u6a29\u8005\u3001\u3068\u308a\u308f\u3051\u512a\u5148\u6a29\u306e\u8b72\u6e21\u304c\u306a\u3044\u3053\u3068\u306b\u8d77\u56e0\u3059\u308b\u6570\u591a\u304f\u306e\u56f0\u96e3\u306b\u76f4\u9762\u3057\u3066\u3044\u308b\u7c73\u56fd\u306e\u7279\u8a31\u6a29\u8005\u306b\u3068\u3063\u3066\uff08\u975e\u5e38\u306b\uff09\u6709\u5229\u306a\u3082\u306e\u3067\u3059\u3002\u5916\u89b3\u7406\u8ad6\uff08\u3059\u306a\u308f\u3061\u3001\u5b50\u4f1a\u793e\u304c\u7279\u8a31\u6a29\u8005\u306e\u3088\u3046\u306b\u632f\u308b\u821e\u3046\u3053\u3068\uff09\u306b\u57fa\u3065\u304f\u5b9f\u969b\u7684\u306a\u89e3\u91c8\u306f\u8208\u5473\u6df1\u3044\u3082\u306e\u3067\u3059\u304c\u3001\u305d\u308c\u306f\u3001\u512a\u5148\u6a29\u304c\u5358\u306b\u9069\u5207\u306b\u8b72\u6e21\u3055\u308c\u3066\u3044\u306a\u304b\u3063\u305f\u3068\u3044\u3046\u4e8b\u5b9f\u3092\u8986\u3044\u96a0\u3059\u305f\u3081\u306e\u6570\u591a\u304f\u306e\u6df7\u540c\u306e\u7523\u7269\u3067\u3059\u3002\u5b9f\u969b\u3001\u7279\u8a31\u306e\u627f\u7d99\u306f\u5fc5\u305a\u3057\u3082\u512a\u5148\u6a29\u306e\u627f\u7d99\u3092\u610f\u5473\u3057\u307e\u305b\u3093\u3002\u512a\u5148\u6a29\u306f\u72ec\u7acb\u3057\u3066\u8b72\u6e21\u3055\u308c\u5f97\u308b\u304b\u3089\u3067\u3059\u3002\u307e\u305f\u3001\u3042\u308b\u4f1a\u793e\u304c\u30b0\u30eb\u30fc\u30d7\u306b\u5c5e\u3057\u3066\u3044\u308b\u3068\u3044\u3046\u4e8b\u5b9f\u306f\u3001\u305d\u306e\u3059\u3079\u3066\u306e\u8cc7\u7523\u304c\u89aa\u4f1a\u793e\u306b\u79fb\u8ee2\u3055\u308c\u306a\u3051\u308c\u3070\u306a\u3089\u306a\u3044\u3053\u3068\u3092\u610f\u5473\u3057\u307e\u305b\u3093\u3002\u305d\u3057\u3066\u3001<em>last but not least<\/em>\u3001\u672c\u4ef6\u306e\u3088\u3046\u306b\u3001\u512a\u5148\u6a29\u304c\u4e00\u5ea6\u3082\u8b72\u6e21\u3055\u308c\u3066\u3044\u306a\u3044\u305f\u3081\u6a29\u5229\u306e\u9023\u9396\u304c\u5f53\u521d\u304b\u3089\u65ad\u7d76\u3057\u3066\u3044\u308b\u5834\u5408\u3001\u305d\u306e\u5f8c\u306e\u3044\u304b\u306a\u308b\u884c\u70ba\u304c\u3069\u306e\u3088\u3046\u306b\u3057\u3066\u305d\u306e\u72b6\u6cc1\u3092\u662f\u6b63\u3057\u5f97\u308b\u306e\u304b\u3001\u79c1\u306b\u306f\u7406\u89e3\u3057\u96e3\u3044\u3068\u3053\u308d\u3067\u3059\u3002\u6700\u5f8c\u306b\u3001\u5916\u89b3\u7406\u8ad6\uff08\u3059\u306a\u308f\u3061\u3001\u4ed6\u8005\u306b\u5bfe\u3057\u3066\u6240\u6709\u8005\u306e\u3088\u3046\u306b\u632f\u308b\u821e\u3046\u3053\u3068\u3067\u3001\u8ca1\u7523\u6a29\u306e\u6240\u6709\u8005\u306e\u5916\u89b3\u304c\u751f\u3058\u308b\u3053\u3068\uff09\u306f\u5bb9\u6613\u306b\u7406\u89e3\u3067\u304d\u308b\u3082\u306e\u306e\u3001\u4f55\u3089\u306e\u6a29\u5229\u3082\u8b72\u6e21\u3055\u308c\u3066\u3044\u306a\u3044\u5225\u4f1a\u793e\u3067\u3042\u308b\u5b50\u4f1a\u793e\u304c\u3001\u89aa\u4f1a\u793e\u3068\u540c\u69d8\u306b\u3053\u306e\u7406\u8ad6\u306e\u6069\u6075\u3092\u53d7\u3051\u5f97\u308b\u3068\u306f\u3001\u306a\u304b\u306a\u304b\u8003\u3048\u96e3\u3044\u3068\u3053\u308d\u3067\u3059\u3002\u6b8b\u5ff5\u306a\u304c\u3089\u3001\u3053\u308c\u306f\u7279\u8a31\u6a29\u8005\u306b\u5bfe\u3057\u512a\u5148\u6a29\u306e\u8b72\u6e21\u3092\u9069\u5207\u306b\u5f62\u5f0f\u5316\u3059\u308b\u3088\u3046\u4fc3\u3059\u3082\u306e\u3067\u306f\u306a\u304f\u3001\u7279\u8a31\u5236\u5ea6\u5168\u4f53\u3092\u898b\u6e21\u3059\u306a\u3089\u3070\u3001\u8cdb\u540c\u3059\u308b\u3053\u3068\u306f\u3067\u304d\u307e\u305b\u3093\u3002\u5f62\u5f0f\u4e3b\u7fa9\u306f\u3001\u3053\u306e\u5236\u5ea6\u306e\u5229\u7528\u8005\u3092\u7169\u308f\u305b\u308b\u305f\u3081\uff08\u3060\u3051\uff09\u306b\u5b58\u5728\u3059\u308b\u306e\u3067\u306f\u306a\u304f\u3001\u5236\u5ea6\u304c\u6b63\u3057\u304f\u6a5f\u80fd\u3057\u3001\u672c\u4ef6\u306b\u304a\u3044\u3066\u306f\u8ab0\u304c\u6a29\u5229\u8005\u3067\u3042\u308b\u304b\u3092\u660e\u78ba\u306b\u793a\u3059\u3053\u3068\u304c\u3067\u304d\u308b\u3088\u3046\u306b\u3059\u308b\u305f\u3081\u306b\u3082\u5b58\u5728\u3059\u308b\u306e\u3067\u3059\u3002<\/p>\n<p>\u7d50\u8ad6\u3068\u3057\u3066\u3001\u672c\u5224\u6c7a\u304c\u7279\u8a31\u6a29\u8005\u306b\u6709\u5229\u306a\u3082\u306e\u3067\u3042\u308b\u3053\u3068\u3001\u7d71\u4e00\u7279\u8a31\u88c1\u5224\u6240\uff08UPC\uff09\u306e\u5e55\u958b\u3051\u306b\u3042\u305f\u308a\u3001\u30d5\u30e9\u30f3\u30b9\u306e\u88c1\u5224\u5b98\u304c\u4eca\u5f8c\u3082\u3001\u305d\u3057\u3066\u304a\u305d\u3089\u304f\u3053\u308c\u307e\u3067\u4ee5\u4e0a\u306b\u767a\u8a00\u6a29\u3092\u6301\u3061\u7d9a\u3051\u308b\u3053\u3068\u3092\u60f3\u8d77\u3055\u305b\u3066\u3044\u308b\u3053\u3068\u3001\u305d\u3057\u3066\u30d5\u30e9\u30f3\u30b9\u3067\u6570\u5e74\u6765\u9032\u884c\u3057\u3066\u3044\u308b\u3053\u306e\u50be\u5411\u304c\u3059\u3050\u306b\u9014\u7d76\u3048\u308b\u53ef\u80fd\u6027\u306f\u4f4e\u3044\u3053\u3068\u306b\u306f\u3001\u307b\u3068\u3093\u3069\u7591\u3044\u306e\u4f59\u5730\u304c\u3042\u308a\u307e\u305b\u3093\u3002<em>Cour de Cassation<\/em>\u304c\u3001\u3053\u306e\u79cb\u3001\u30d1\u30ea<em>Tribunal Judiciaire<\/em>\u306e\u6700\u3082\u5353\u8d8a\u3057\u305f\u7279\u8a31\u6cd5\u306e\u5c02\u9580\u5bb6\u3092\u8fce\u3048\u5165\u308c\u308b\u304b\u3089\u3067\u3059\u3002<\/p>\n<p><\/p>\n","protected":false},"excerpt":{"rendered":"","protected":false},"author":4,"featured_media":17394,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[29,16,28],"tags":[],"class_list":["post-10070","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-brevetabilite","category-brevets","category-pharmaceutique"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.7 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Apixaban Case in France: Priority to the Patentee | Dhenne Avocats<\/title>\n<meta name=\"description\" content=\"Dhenne Avocats reviews the Apixaban decision in France and what it means for patentees seeking preliminary relief in pharmaceutical patent disputes.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.dhenne-avocats.fr\/ja\/apixaban-case-in-france-priority-to-the-patentee\/\" \/>\n<meta property=\"og:locale\" content=\"ja_JP\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Apixaban Case in France: Priority to the Patentee | Dhenne Avocats\" \/>\n<meta property=\"og:description\" content=\"Dhenne Avocats reviews the Apixaban decision in France and what it means for patentees seeking preliminary relief in pharmaceutical patent disputes.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.dhenne-avocats.fr\/ja\/apixaban-case-in-france-priority-to-the-patentee\/\" \/>\n<meta property=\"og:site_name\" content=\"Dhenne Avocats\" \/>\n<meta property=\"article:published_time\" content=\"2023-07-25T12:30:25+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-10-23T16:22:54+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.dhenne-avocats.fr\/wp-content\/uploads\/2026\/10\/og-dhenne-avocats-fr.png\" \/>\n\t<meta property=\"og:image:width\" content=\"1200\" \/>\n\t<meta property=\"og:image:height\" content=\"630\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Matthieu Dhenne\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@matthieu_dhenne\" \/>\n<meta name=\"twitter:site\" content=\"@DhenneAvocats\" \/>\n<meta name=\"twitter:label1\" content=\"\u57f7\u7b46\u8005\" \/>\n\t<meta name=\"twitter:data1\" content=\"Matthieu Dhenne\" \/>\n\t<meta name=\"twitter:label2\" content=\"\u63a8\u5b9a\u8aad\u307f\u53d6\u308a\u6642\u9593\" \/>\n\t<meta name=\"twitter:data2\" content=\"13\u5206\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.dhenne-avocats.fr\\\/apixaban-case-in-france-priority-to-the-patentee\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.dhenne-avocats.fr\\\/apixaban-case-in-france-priority-to-the-patentee\\\/\"},\"author\":{\"name\":\"Matthieu Dhenne\",\"@id\":\"https:\\\/\\\/www.dhenne-avocats.fr\\\/#\\\/schema\\\/person\\\/cebb642899b1d41301d41a0187fa329c\"},\"headline\":\"APIXABAN case in France: priority to the patentee\",\"datePublished\":\"2023-07-25T12:30:25+00:00\",\"dateModified\":\"2026-10-23T16:22:54+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.dhenne-avocats.fr\\\/apixaban-case-in-france-priority-to-the-patentee\\\/\"},\"wordCount\":357,\"publisher\":{\"@id\":\"https:\\\/\\\/www.dhenne-avocats.fr\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/www.dhenne-avocats.fr\\\/apixaban-case-in-france-priority-to-the-patentee\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.dhenne-avocats.fr\\\/wp-content\\\/uploads\\\/2026\\\/10\\\/dhenne-art-yellow-red-blue.webp\",\"articleSection\":[\"Brevetabilit\u00e9\",\"Brevets\",\"Pharmaceutique\"],\"inLanguage\":\"ja\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.dhenne-avocats.fr\\\/apixaban-case-in-france-priority-to-the-patentee\\\/\",\"url\":\"https:\\\/\\\/www.dhenne-avocats.fr\\\/apixaban-case-in-france-priority-to-the-patentee\\\/\",\"name\":\"Apixaban Case in France: Priority to the Patentee | Dhenne Avocats\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.dhenne-avocats.fr\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.dhenne-avocats.fr\\\/apixaban-case-in-france-priority-to-the-patentee\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.dhenne-avocats.fr\\\/apixaban-case-in-france-priority-to-the-patentee\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.dhenne-avocats.fr\\\/wp-content\\\/uploads\\\/2026\\\/10\\\/dhenne-art-yellow-red-blue.webp\",\"datePublished\":\"2023-07-25T12:30:25+00:00\",\"dateModified\":\"2026-10-23T16:22:54+00:00\",\"description\":\"Dhenne Avocats reviews the Apixaban decision in France and what it means for patentees seeking preliminary relief in pharmaceutical patent disputes.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.dhenne-avocats.fr\\\/apixaban-case-in-france-priority-to-the-patentee\\\/#breadcrumb\"},\"inLanguage\":\"ja\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.dhenne-avocats.fr\\\/apixaban-case-in-france-priority-to-the-patentee\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"ja\",\"@id\":\"https:\\\/\\\/www.dhenne-avocats.fr\\\/apixaban-case-in-france-priority-to-the-patentee\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.dhenne-avocats.fr\\\/wp-content\\\/uploads\\\/2026\\\/10\\\/dhenne-art-yellow-red-blue.webp\",\"contentUrl\":\"https:\\\/\\\/www.dhenne-avocats.fr\\\/wp-content\\\/uploads\\\/2026\\\/10\\\/dhenne-art-yellow-red-blue.webp\",\"width\":1280,\"height\":824,\"caption\":\"Vassily Kandinsky, Jaune-Rouge-Bleu, 1925. Centre Pompidou, Mus\u00e9e national d\u2019art moderne. \u2014 Source \u00b7 Domaine public. Format optimis\u00e9 pour le web.\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.dhenne-avocats.fr\\\/apixaban-case-in-france-priority-to-the-patentee\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Accueil\",\"item\":\"https:\\\/\\\/www.dhenne-avocats.fr\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"APIXABAN case in France: priority to the patentee\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.dhenne-avocats.fr\\\/#website\",\"url\":\"https:\\\/\\\/www.dhenne-avocats.fr\\\/\",\"name\":\"Dhenne Avocats\",\"description\":\"Cabinet d&#039;avocats en droit des brevets\",\"publisher\":{\"@id\":\"https:\\\/\\\/www.dhenne-avocats.fr\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.dhenne-avocats.fr\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"ja\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/www.dhenne-avocats.fr\\\/#organization\",\"name\":\"Dhenne Avocats\",\"alternateName\":\"dhenne avocats\",\"url\":\"https:\\\/\\\/www.dhenne-avocats.fr\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"ja\",\"@id\":\"https:\\\/\\\/www.dhenne-avocats.fr\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/www.dhenne-avocats.fr\\\/wp-content\\\/uploads\\\/2024\\\/03\\\/cropped-DhenneAvocats_Favicon_RVB_FullColor-1.png\",\"contentUrl\":\"https:\\\/\\\/www.dhenne-avocats.fr\\\/wp-content\\\/uploads\\\/2024\\\/03\\\/cropped-DhenneAvocats_Favicon_RVB_FullColor-1.png\",\"width\":512,\"height\":512,\"caption\":\"Dhenne Avocats\"},\"image\":{\"@id\":\"https:\\\/\\\/www.dhenne-avocats.fr\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/x.com\\\/DhenneAvocats\",\"https:\\\/\\\/www.linkedin.com\\\/company\\\/dhenne-avocat\\\/\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.dhenne-avocats.fr\\\/#\\\/schema\\\/person\\\/cebb642899b1d41301d41a0187fa329c\",\"name\":\"Matthieu Dhenne\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"ja\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/988db4ff705a27432f0176d0317044da13eaf4eee82d9246f7cf81f2504e05c4?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/988db4ff705a27432f0176d0317044da13eaf4eee82d9246f7cf81f2504e05c4?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/988db4ff705a27432f0176d0317044da13eaf4eee82d9246f7cf81f2504e05c4?s=96&d=mm&r=g\",\"caption\":\"Matthieu Dhenne\"},\"description\":\"Avocat au barreau de Paris depuis 2014, docteur en droit, fondateur de Dhenne Avocats, cabinet d\u00e9di\u00e9 au contentieux des brevets d\u2019invention. Repr\u00e9sentant devant la Juridiction unifi\u00e9e du brevet. Enseigne le droit de la propri\u00e9t\u00e9 industrielle \u00e0 l\u2019Universit\u00e9 Panth\u00e9on-Assas et assure la correspondance fran\u00e7aise du Kluwer Patent Blog.\",\"sameAs\":[\"https:\\\/\\\/www.dhenne-avocats.fr\\\/equipe-nos-avocats-brevets\\\/matthieu-dhenne\\\/\",\"https:\\\/\\\/www.linkedin.com\\\/in\\\/matthieudhenne\\\/\",\"https:\\\/\\\/x.com\\\/matthieu_dhenne\"]}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"\u30d5\u30e9\u30f3\u30b9\u306b\u304a\u3051\u308bApixaban\u4e8b\u4ef6\uff1a\u7279\u8a31\u6a29\u8005\u3092\u512a\u5148 | Dhenne Avocats","description":"Dhenne Avocats\u304c\u3001\u30d5\u30e9\u30f3\u30b9\u306b\u304a\u3051\u308bApixaban\u5224\u6c7a\u3092\u691c\u8a0e\u3057\u3001\u533b\u85ac\u54c1\u7279\u8a31\u7d1b\u4e89\u306b\u304a\u3044\u3066\u66ab\u5b9a\u7684\u6551\u6e08\u3092\u6c42\u3081\u308b\u7279\u8a31\u6a29\u8005\u306b\u3068\u3063\u3066\u306e\u610f\u7fa9\u3092\u89e3\u8aac\u3057\u307e\u3059\u3002","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.dhenne-avocats.fr\/ja\/apixaban-case-in-france-priority-to-the-patentee\/","og_locale":"ja_JP","og_type":"article","og_title":"Apixaban Case in France: Priority to the Patentee | Dhenne Avocats","og_description":"Dhenne Avocats reviews the Apixaban decision in France and what it means for patentees seeking preliminary relief in pharmaceutical patent disputes.","og_url":"https:\/\/www.dhenne-avocats.fr\/ja\/apixaban-case-in-france-priority-to-the-patentee\/","og_site_name":"Dhenne Avocats","article_published_time":"2023-07-25T12:30:25+00:00","article_modified_time":"2026-10-23T16:22:54+00:00","og_image":[{"width":1200,"height":630,"url":"https:\/\/www.dhenne-avocats.fr\/wp-content\/uploads\/2026\/10\/og-dhenne-avocats-fr.png","type":"image\/png"}],"author":"Matthieu Dhenne","twitter_card":"summary_large_image","twitter_creator":"@matthieu_dhenne","twitter_site":"@DhenneAvocats","twitter_misc":{"\u57f7\u7b46\u8005":"Matthieu Dhenne","\u63a8\u5b9a\u8aad\u307f\u53d6\u308a\u6642\u9593":"13\u5206"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.dhenne-avocats.fr\/apixaban-case-in-france-priority-to-the-patentee\/#article","isPartOf":{"@id":"https:\/\/www.dhenne-avocats.fr\/apixaban-case-in-france-priority-to-the-patentee\/"},"author":{"name":"Matthieu Dhenne","@id":"https:\/\/www.dhenne-avocats.fr\/#\/schema\/person\/cebb642899b1d41301d41a0187fa329c"},"headline":"APIXABAN case in France: priority to the patentee","datePublished":"2023-07-25T12:30:25+00:00","dateModified":"2026-10-23T16:22:54+00:00","mainEntityOfPage":{"@id":"https:\/\/www.dhenne-avocats.fr\/apixaban-case-in-france-priority-to-the-patentee\/"},"wordCount":357,"publisher":{"@id":"https:\/\/www.dhenne-avocats.fr\/#organization"},"image":{"@id":"https:\/\/www.dhenne-avocats.fr\/apixaban-case-in-france-priority-to-the-patentee\/#primaryimage"},"thumbnailUrl":"https:\/\/www.dhenne-avocats.fr\/wp-content\/uploads\/2026\/10\/dhenne-art-yellow-red-blue.webp","articleSection":["Brevetabilit\u00e9","Brevets","Pharmaceutique"],"inLanguage":"ja"},{"@type":"WebPage","@id":"https:\/\/www.dhenne-avocats.fr\/apixaban-case-in-france-priority-to-the-patentee\/","url":"https:\/\/www.dhenne-avocats.fr\/apixaban-case-in-france-priority-to-the-patentee\/","name":"\u30d5\u30e9\u30f3\u30b9\u306b\u304a\u3051\u308bApixaban\u4e8b\u4ef6\uff1a\u7279\u8a31\u6a29\u8005\u3092\u512a\u5148 | Dhenne Avocats","isPartOf":{"@id":"https:\/\/www.dhenne-avocats.fr\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.dhenne-avocats.fr\/apixaban-case-in-france-priority-to-the-patentee\/#primaryimage"},"image":{"@id":"https:\/\/www.dhenne-avocats.fr\/apixaban-case-in-france-priority-to-the-patentee\/#primaryimage"},"thumbnailUrl":"https:\/\/www.dhenne-avocats.fr\/wp-content\/uploads\/2026\/10\/dhenne-art-yellow-red-blue.webp","datePublished":"2023-07-25T12:30:25+00:00","dateModified":"2026-10-23T16:22:54+00:00","description":"Dhenne Avocats\u304c\u3001\u30d5\u30e9\u30f3\u30b9\u306b\u304a\u3051\u308bApixaban\u5224\u6c7a\u3092\u691c\u8a0e\u3057\u3001\u533b\u85ac\u54c1\u7279\u8a31\u7d1b\u4e89\u306b\u304a\u3044\u3066\u66ab\u5b9a\u7684\u6551\u6e08\u3092\u6c42\u3081\u308b\u7279\u8a31\u6a29\u8005\u306b\u3068\u3063\u3066\u306e\u610f\u7fa9\u3092\u89e3\u8aac\u3057\u307e\u3059\u3002","breadcrumb":{"@id":"https:\/\/www.dhenne-avocats.fr\/apixaban-case-in-france-priority-to-the-patentee\/#breadcrumb"},"inLanguage":"ja","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.dhenne-avocats.fr\/apixaban-case-in-france-priority-to-the-patentee\/"]}]},{"@type":"ImageObject","inLanguage":"ja","@id":"https:\/\/www.dhenne-avocats.fr\/apixaban-case-in-france-priority-to-the-patentee\/#primaryimage","url":"https:\/\/www.dhenne-avocats.fr\/wp-content\/uploads\/2026\/10\/dhenne-art-yellow-red-blue.webp","contentUrl":"https:\/\/www.dhenne-avocats.fr\/wp-content\/uploads\/2026\/10\/dhenne-art-yellow-red-blue.webp","width":1280,"height":824,"caption":"Vassily Kandinsky, Jaune-Rouge-Bleu, 1925. Centre Pompidou, Mus\u00e9e national d\u2019art moderne. \u2014 Source \u00b7 Domaine public. Format optimis\u00e9 pour le web."},{"@type":"BreadcrumbList","@id":"https:\/\/www.dhenne-avocats.fr\/apixaban-case-in-france-priority-to-the-patentee\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Accueil","item":"https:\/\/www.dhenne-avocats.fr\/"},{"@type":"ListItem","position":2,"name":"APIXABAN case in France: priority to the patentee"}]},{"@type":"WebSite","@id":"https:\/\/www.dhenne-avocats.fr\/#website","url":"https:\/\/www.dhenne-avocats.fr\/","name":"Dhenne Avocats","description":"\u30d1\u30ea\u306e\u7279\u8a31\u8a34\u8a1f\u30d6\u30c6\u30a3\u30c3\u30af","publisher":{"@id":"https:\/\/www.dhenne-avocats.fr\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.dhenne-avocats.fr\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"ja"},{"@type":"Organization","@id":"https:\/\/www.dhenne-avocats.fr\/#organization","name":"Dhenne Avocats","alternateName":"dhenne avocats","url":"https:\/\/www.dhenne-avocats.fr\/","logo":{"@type":"ImageObject","inLanguage":"ja","@id":"https:\/\/www.dhenne-avocats.fr\/#\/schema\/logo\/image\/","url":"https:\/\/www.dhenne-avocats.fr\/wp-content\/uploads\/2024\/03\/cropped-DhenneAvocats_Favicon_RVB_FullColor-1.png","contentUrl":"https:\/\/www.dhenne-avocats.fr\/wp-content\/uploads\/2024\/03\/cropped-DhenneAvocats_Favicon_RVB_FullColor-1.png","width":512,"height":512,"caption":"Dhenne Avocats"},"image":{"@id":"https:\/\/www.dhenne-avocats.fr\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/x.com\/DhenneAvocats","https:\/\/www.linkedin.com\/company\/dhenne-avocat\/"]},{"@type":"Person","@id":"https:\/\/www.dhenne-avocats.fr\/#\/schema\/person\/cebb642899b1d41301d41a0187fa329c","name":"\u30de\u30c1\u30e5\u30fc\u30fb\u30c7\u30f3\u30cc","image":{"@type":"ImageObject","inLanguage":"ja","@id":"https:\/\/secure.gravatar.com\/avatar\/988db4ff705a27432f0176d0317044da13eaf4eee82d9246f7cf81f2504e05c4?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/988db4ff705a27432f0176d0317044da13eaf4eee82d9246f7cf81f2504e05c4?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/988db4ff705a27432f0176d0317044da13eaf4eee82d9246f7cf81f2504e05c4?s=96&d=mm&r=g","caption":"Matthieu Dhenne"},"description":"Avocat au barreau de Paris depuis 2014, docteur en droit, fondateur de Dhenne Avocats, cabinet d\u00e9di\u00e9 au contentieux des brevets d\u2019invention. Repr\u00e9sentant devant la Juridiction unifi\u00e9e du brevet. Enseigne le droit de la propri\u00e9t\u00e9 industrielle \u00e0 l\u2019Universit\u00e9 Panth\u00e9on-Assas et assure la correspondance fran\u00e7aise du Kluwer Patent Blog.","sameAs":["https:\/\/www.dhenne-avocats.fr\/equipe-nos-avocats-brevets\/matthieu-dhenne\/","https:\/\/www.linkedin.com\/in\/matthieudhenne\/","https:\/\/x.com\/matthieu_dhenne"]}]}},"_links":{"self":[{"href":"https:\/\/www.dhenne-avocats.fr\/ja\/wp-json\/wp\/v2\/posts\/10070","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.dhenne-avocats.fr\/ja\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.dhenne-avocats.fr\/ja\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.dhenne-avocats.fr\/ja\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/www.dhenne-avocats.fr\/ja\/wp-json\/wp\/v2\/comments?post=10070"}],"version-history":[{"count":4,"href":"https:\/\/www.dhenne-avocats.fr\/ja\/wp-json\/wp\/v2\/posts\/10070\/revisions"}],"predecessor-version":[{"id":17206,"href":"https:\/\/www.dhenne-avocats.fr\/ja\/wp-json\/wp\/v2\/posts\/10070\/revisions\/17206"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.dhenne-avocats.fr\/ja\/wp-json\/wp\/v2\/media\/17394"}],"wp:attachment":[{"href":"https:\/\/www.dhenne-avocats.fr\/ja\/wp-json\/wp\/v2\/media?parent=10070"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.dhenne-avocats.fr\/ja\/wp-json\/wp\/v2\/categories?post=10070"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.dhenne-avocats.fr\/ja\/wp-json\/wp\/v2\/tags?post=10070"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}